RedHill’s oral drug boosts Veklury efficacy in severe COVID

An oral drug developed by RedHill Biopharma has reduced mortality in severe COVID-19 patients when added to therapy with corticosteroids and Gilead Science’s intravenous antiviral Veklury, setting up regulatory filings.